BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 8735551)

  • 1. Molecular size characterization of Haemophilus influenzae type b polysaccharide-protein conjugate vaccines.
    Plumb JE; Yost SE
    Vaccine; 1996 Apr; 14(5):399-404. PubMed ID: 8735551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of Haemophilus influenzae type b conjugate vaccine prepared using different polysaccharide chain lengths.
    Rana R; Dalal J; Singh D; Kumar N; Hanif S; Joshi N; Chhikara MK
    Vaccine; 2015 May; 33(23):2646-54. PubMed ID: 25907408
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stability testing in Haemophilus influenzae type b conjugate vaccines.
    Klug B
    Dev Biol Stand; 1996; 87():263-7. PubMed ID: 8854026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines after treatment of Hodgkin disease.
    Molrine DC; George S; Tarbell N; Mauch P; Diller L; Neuberg D; Shamberger RC; Anderson EL; Phillips NR; Kinsella K; Ambrosino DM
    Ann Intern Med; 1995 Dec; 123(11):828-34. PubMed ID: 7486464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide.
    Sturgess AW; Rush K; Charbonneau RJ; Lee JI; West DJ; Sitrin RD; Hennessy JP
    Vaccine; 1999 Mar; 17(9-10):1169-78. PubMed ID: 10195629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel enzyme-linked immuno-sorbent assay (ELISA) for the quantification of total and free polysaccharide in Haemophilus influenzae b-Tetanus toxoid conjugate vaccines in monovalent and combined vaccine formulations.
    Saydam M; Rigsby P; Mawas F
    Biologicals; 2014 Jan; 42(1):29-33. PubMed ID: 24200313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
    Dashefsky B; Wald E; Guerra N; Byers C
    Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a guinea pig model to assess immunogenicity of Haemophilus influenzae type b capsular polysaccharide conjugate vaccines.
    Siber GR; Anderson R; Habafy M; Gupta RK
    Vaccine; 1995 Apr; 13(6):525-31. PubMed ID: 7483772
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Size fractionation of bacterial capsular polysaccharides for their use in conjugate vaccines.
    Costantino P; Norelli F; Giannozzi A; D'Ascenzi S; Bartoloni A; Kaur S; Tang D; Seid R; Viti S; Paffetti R; Bigio M; Pennatini C; Averani G; Guarnieri V; Gallo E; Ravenscroft N; Lazzeroni C; Rappuoli R; Ceccarini C
    Vaccine; 1999 Mar; 17(9-10):1251-63. PubMed ID: 10195638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of physico-chemical modification on the immunogenicity of Haemophilus influenzae type b oligosaccharide-CRM(197) conjugate vaccines.
    Bolgiano B; Mawas F; Yost SE; Crane DT; Lemercinier X; Corbel MJ
    Vaccine; 2001 Apr; 19(23-24):3189-200. PubMed ID: 11312015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of Haemophilus influenzae type b disease.
    Santosham M
    Vaccine; 1993; 11 Suppl 1():S52-7. PubMed ID: 8447177
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Study of the chemical stability of the capsular polysaccharide produced by Haemophilus influenzae type b.
    Cintra Fde O; Takagi M
    Carbohydr Polym; 2015 Feb; 116():167-72. PubMed ID: 25458286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity and immunogenicity profiles of a novel pentavalent diphtheria-tetanus-whole cell pertussis-hepatitis B and Haemophilus influenzae type B vaccine: a randomized dose-ranging trial of the Hib tetanus-conjugate content.
    Hla KH; Thein SA; Aye A; Han HH; Bock HL; David MP; Schuerman L
    Pediatr Infect Dis J; 2006 Aug; 25(8):706-12. PubMed ID: 16874170
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the saccharide content and stability of the first WHO International Standard for Haemophilus influenzae b capsular polysaccharide.
    Mawas F; Bolgiano B; Rigsby P; Crane D; Belgrave D; Corbel MJ
    Biologicals; 2007 Oct; 35(4):235-45. PubMed ID: 17337205
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus influenzae type b in PRP-tetanus toxoid conjugate vaccine.
    Guo YY; Anderson R; McIver J; Gupta RK; Siber GR
    Biologicals; 1998 Mar; 26(1):33-8. PubMed ID: 9637747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection.
    Tsai CM; Gu XX; Byrd RA
    Vaccine; 1994 Jun; 12(8):700-6. PubMed ID: 8091847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Postlicensure effectiveness of the Haemophilus influenzae type b polysaccharide-Neisseria meningitidis outer-membrane protein complex conjugate vaccine among Navajo children.
    Harrison LH; Tajkowski C; Croll J; Reid R; Hu D; Brenneman G; Weatherholtz RC; Santosham M
    J Pediatr; 1994 Oct; 125(4):571-6. PubMed ID: 7931875
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of two Haemophilus influenzae type b conjugate vaccines.
    Matjila MJ; Phohu TC; Banzhoff A; Viviani S; Hoosen AA; Bianchini M; Nacci P; Palweni CW; Podda A; Whitfield M; Aspinall S
    S Afr Med J; 2004 Jan; 94(1):43-6. PubMed ID: 14971232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a guinea-pig model for potency/immunogenicity evaluation of diphtheria, tetanus acellular pertussis (DTaP) and Haemophilus influenzae type b polysaccharide conjugate vaccines.
    Gupta RK; Anderson R; Cecchini D; Rost B; Griffin P; Benscoter K; Xu J; Montanez-Ortiz L; Siber GR
    Dev Biol Stand; 1996; 86():283-96. PubMed ID: 8785957
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formulation and characterisation of Bordetella pertussis fimbriae as novel carrier proteins for Hib conjugate vaccines.
    Crowley-Luke A; Reddin K; Gorringe A; Hudson MJ; Robinson A
    Vaccine; 2001 May; 19(25-26):3399-407. PubMed ID: 11348704
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.